Skip to content
OpenCapital
Get started

Exelixis EXEL Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
——
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
ALN
Alnylam PharmaceuticalsALNY
——
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
——

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's proceeds from exercises of stock options and other stock issuances?
Exelixis (EXEL) reported proceeds from exercises of stock options and other stock issuances of $7.47M in Q1 2026.
How has Exelixis's proceeds from exercises of stock options and other stock issuances changed year-over-year?
Exelixis's proceeds from exercises of stock options and other stock issuances decreased by 35.7% year-over-year, from $11.63M to $7.47M.
What is the long-term trend for Exelixis's proceeds from exercises of stock options and other stock issuances?
Over 4 years (2021 to 2025), Exelixis's proceeds from exercises of stock options and other stock issuances has grown at a 19.2% compound annual growth rate (CAGR), from $24.31M to $49.14M.